It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The disease-causing blood-stage of the Plasmodium falciparum lifecycle begins with invasion of human erythrocytes by merozoites. Many vaccine candidates with key roles in binding to the erythrocyte surface and entry are secreted from the large bulb-like rhoptry organelles at the apical tip of the merozoite. Here we identify an essential role for the conserved protein P. falciparum Cytosolically Exposed Rhoptry Leaflet Interacting protein 1 (PfCERLI1) in rhoptry function. We show that PfCERLI1 localises to the cytosolic face of the rhoptry bulb membrane and knockdown of PfCERLI1 inhibits merozoite invasion. While schizogony and merozoite organelle biogenesis appear normal, biochemical techniques and semi-quantitative super-resolution microscopy show that PfCERLI1 knockdown prevents secretion of key rhoptry antigens that coordinate merozoite invasion. PfCERLI1 is a rhoptry associated protein identified to have a direct role in function of this essential merozoite invasion organelle, which has broader implications for understanding apicomplexan invasion biology.
Rhoptries are essential organelles for invasion of erythrocytes by Plasmodium. Here, the authors characterize the rhoptry-associated protein CERLI1 using quantitative super-resolution microscopy, showing that it is important for parasite invasion and secretion of rhoptry proteins including vaccine antigens.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Adelaide, Research Centre for Infectious Diseases, School of Biological Sciences, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304)
2 University of South Australia Cancer Research Institute, Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, Adelaide, Australia (GRID:grid.1026.5) (ISNI:0000 0000 8994 5086)
3 The University of Melbourne, Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
4 Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (GRID:grid.424065.1) (ISNI:0000 0001 0701 3136); Centre for Structural Systems Biology, Hamburg, Germany (GRID:grid.424065.1); University of Hamburg, Biology Department, Hamburg, Germany (GRID:grid.9026.d) (ISNI:0000 0001 2287 2617)
5 University of Adelaide, Research Centre for Infectious Diseases, School of Biological Sciences, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304); Burnet Institute, Melbourne, Australia (GRID:grid.1056.2) (ISNI:0000 0001 2224 8486)